about
Critical role of acetylation in tau-mediated neurodegeneration and cognitive deficitsSmall molecule p75NTR ligands reduce pathological phosphorylation and misfolding of tau, inflammatory changes, cholinergic degeneration, and cognitive deficits in AβPP(L/S) transgenic mice.Tau deposition drives neuropathological, inflammatory and behavioral abnormalities independently of neuronal loss in a novel mouse modelOral zinc reduces amyloid burden in Tg2576 micePreliminary Study of Plasma Exosomal Tau as a Potential Biomarker for Chronic Traumatic Encephalopathy."Tau oligomers," what we know and what we don't know.Biochemical Distribution of Tau Protein in Synaptosomal Fraction of Transgenic Mice Expressing Human P301L Tau.Regional distribution of synaptic markers and APP correlate with distinct clinicopathological features in sporadic and familial Alzheimer's disease.Glycan Determinants of Heparin-Tau Interaction.The C9ORF72 GGGGCC expansion forms RNA G-quadruplex inclusions and sequesters hnRNP H to disrupt splicing in ALS brains.Brain ureido degenerative protein modifications are associated with neuroinflammation and proteinopathy in Alzheimer's disease with cerebrovascular disease.Stages and conformations of the Tau repeat domain during aggregation and its effect on neuronal toxicityColocalization of phosphorylated forms of WAVE1, CRMP2, and tau in Alzheimer's disease model mice: Involvement of Cdk5 phosphorylation and the effect of ATRA treatment.Longitudinal evaluation of Tau-P301L transgenic mice reveals no cognitive impairments at 17 months of age.Tau Fibril Formation in Cultured Cells Compatible with a Mouse Model of Tauopathy.
P2860
Q27314989-6C38D73F-7DB4-4B6B-8EC1-37B59F6FF943Q30611779-26F45D4C-45E4-4A18-8AAC-DB980DAFE31AQ30667424-03E85E3D-64AA-46A9-AF25-FB611A6EAE45Q33733571-62E6B6C1-CE12-4AA9-9AF5-56A043DE0355Q36803316-D5525CF8-4B7F-4415-8C4C-76B609AC6311Q37467443-932FCABD-8BBF-4282-9D14-16CB8698B73EQ37629345-5B684C5C-F8DC-40C8-BE46-5674574F94DCQ37723422-C75370EC-37BF-4983-957D-4A17127805C6Q38288698-E884D0FA-3FDF-4714-931A-C57232C4DAFAQ39396328-6018F0F2-E00F-41CA-8612-72422398DC12Q41594978-CB885665-A30D-4719-9020-B008F4FE83C3Q41984715-AFE6DE20-FD65-4D8F-9643-8060CCEA22B5Q52148916-CE51D214-698E-4587-9D44-7493337A93D8Q52641425-1E5444D8-8459-4A96-A546-597E6B751882Q55248848-979AA049-D966-4130-BE87-A1AB8CF313D5
P2860
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 19 July 2013
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Characteristics of tau oligomers.
@en
Characteristics of tau oligomers.
@nl
type
label
Characteristics of tau oligomers.
@en
Characteristics of tau oligomers.
@nl
prefLabel
Characteristics of tau oligomers.
@en
Characteristics of tau oligomers.
@nl
P2860
P356
P1476
Characteristics of tau oligomers.
@en
P2093
Naruhiko Sahara
P2860
P356
10.3389/FNEUR.2013.00102
P577
2013-07-19T00:00:00Z